CoChat

Cannabinoids and the endocannabinoid system in reward processing and addiction: from mechanisms to interventions

Open access
Spanagel, Rainer · 2020 · Dialogues in Clinical Neuroscience

The DOI matches its Crossref record; 72 of the 72 references it cites were found in a registry or an index.

Abstract

The last decades have seen a major gain in understanding the action of cannabinoids and the endocannabinoid system in reward processing and the development of addictive behavior. Cannabis-derived psychoactive compounds such as Δ9-tetrahydrocannabinol and synthetic cannabinoids directly interact with the reward system and thereby have addictive properties. Cannabinoids induce their reinforcing properties by an increase in tonic dopamine levels through a cannabinoid type 1 (CB1) receptor–dependent mechanism within the ventral tegmental area. Cues that are conditioned to cannabis smoking can induce drug-seeking responses (ie, craving) by eliciting phasic dopamine events. A dopamine-independent mechanism involved in drug-seeking responses involves an endocannabinoid/glutamate interaction within the corticostriatal part of the reward system. In conclusion, pharmacological blockade of endocannabinoid signaling should lead to a reduction in drug craving and subsequently should reduce relapse behavior in addicted individuals. Indeed, there is increasing preclinical evidence that targeting the endocannabinoid system reduces craving and relapse, and allosteric modulators at CB1 receptors and fatty acid amide hydrolase inhibitors are in clinical development for cannabis use disorder. Cannabidiol, which mainly acts on CB1 and CB2 receptors, is currently being tested in patients with alcohol use disorder and opioid use disorder.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.31887/dcns.2020.22.3/rspanagel

Cites

72 of 72 references verified0 citation errors · 0 not checkable

Statistics

Figures

Figure 1. Two endocannabinoid-dependent mechanisms have been identified that are involved in mediating natural-reward and drug-seeking responses. A) One mechanism relates to disinhibition of ventral tegmental area (VTA) A10 dopamine neurons by cannabinoid type 1 (CB1) receptor activation.16 Under baseline conditions, dopamine neurons within the VTA are inhibited by GABA through activation of GABAB receptors. Following the presentation of drug-conditioned cues, dopamine neurons switch into phasic firing mode. Through this electrical event, intracellular calcium levels increase, which results in the activation of diacylglycerol lipase (DAGL) and the subsequent synthesis of 2-arachidonylglycerol (2-AG). 2-AG is then postsynaptically released and acts retrogradely at CB1 receptors on GABAergic interneurons. CB1-receptor activation leads to an inhibition of GABA release. This GABA suppression results in disinhibition of dopamine neurons, which further promotes burst firing. Blockade of either GABAB receptors38,39 or CB1 receptors can also inhibit reward-seeking responses through this mechanism. B) The other mechanism relates to endocannabinoid/glutamate interactions within the nucleus accumbens (NAc) glutamatergic afferents from prefrontal regions impinging on D1-medium spiny neurons (D1-MSN). Glutamate-induced activation of metabotropic glutamate receptor 5 (mGluR5) leads to the induction of DAGL and 2-AG synthesis. 2-AG is then released and retrogradely activates Gi/o-coupled CB1 receptors to inhibit further glutamate release. Blockade of either mGluR540,42 or CB1 or CB1 receptors43,44 or CB1 abolishes natural-reward– and drug-reward–seeking responses.36 2-AG, 2-arachidonylglycerol; Ca2+, calcium; CB1, cannabinoid type 1 receptor; DA, dopamine; DAGL, diacylglycerol lipase; mGluR5, metabotropic glutamate receptor 5; MSN, medium spiny neurons; NAc, nucleus accumbens; VTA, ventral tegmental area
Figure 1. Two endocannabinoid-dependent mechanisms have been identified that are involved in mediating natural-reward and drug-seeking responses. A) One mechanism relates to disinhibition of ventral tegmental area (VTA) A10 dopamine neurons by cannabinoid type 1 (CB1) receptor activation.16 Under baseline conditions, dopamine neurons within the VTA are inhibited by GABA through activation of GABAB receptors. Following the presentation of drug-conditioned cues, dopamine neurons switch into phasic firing mode. Through this electrical event, intracellular calcium levels increase, which results in the activation of diacylglycerol lipase (DAGL) and the subsequent synthesis of 2-arachidonylglycerol (2-AG). 2-AG is then postsynaptically released and acts retrogradely at CB1 receptors on GABAergic interneurons. CB1-receptor activation leads to an inhibition of GABA release. This GABA suppression results in disinhibition of dopamine neurons, which further promotes burst firing. Blockade of either GABAB receptors38,39 or CB1 receptors can also inhibit reward-seeking responses through this mechanism. B) The other mechanism relates to endocannabinoid/glutamate interactions within the nucleus accumbens (NAc) glutamatergic afferents from prefrontal regions impinging on D1-medium spiny neurons (D1-MSN). Glutamate-induced activation of metabotropic glutamate receptor 5 (mGluR5) leads to the induction of DAGL and 2-AG synthesis. 2-AG is then released and retrogradely activates Gi/o-coupled CB1 receptors to inhibit further glutamate release. Blockade of either mGluR540,42 or CB1 or CB1 receptors43,44 or CB1 abolishes natural-reward– and drug-reward–seeking responses.36 2-AG, 2-arachidonylglycerol; Ca2+, calcium; CB1, cannabinoid type 1 receptor; DA, dopamine; DAGL, diacylglycerol lipase; mGluR5, metabotropic glutamate receptor 5; MSN, medium spiny neurons; NAc, nucleus accumbens; VTA, ventral tegmental areaCC BY-NC-ND · PubMed Central

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

1 retracted

Show all 72 references

Research works printed but not linked: 2

  1. Peters KZ, 2020, Cold Spring Harb Perspect Med, 21, a03930
  2. Zimmermann US, 2009, Dtsch Arztebl Int, 106, 464

Cited by

See all 127

Metadata

Authors
Spanagel, R.
Affiliations
Heidelberg University (DE)
Corresponding author
Spanagel, Rainer
Venue
Dialogues in Clinical Neuroscience
Published
2020-09-30
Volume
22
Issue
3
Pages
241-250
ISSN
  • 1294-8322 (ISSN-L)
  • 1958-5969
OpenAlex
W3105701481
Cited by
127
References
72
Citations by year
2026: 21 · 2025: 22 · 2024: 29 · 2023: 26 · 2022: 18 · 2021: 10 · 2020: 1
FWCI
8.24
Type
journal article
Language
en
Open access
Locations
  • Dialogues in Clinical Neuroscience (publishedVersion, cc-by-nc-nd)
  • PubMed Central (publishedVersion, cc-by-nc-nd)
  • PubMed (publishedVersion)
Topics
  • Health Sciences › Medicine › Pharmacology (medical) › Cannabis and Cannabinoid Research
  • Life Sciences › Neuroscience › Cellular and Molecular Neuroscience › Neurotransmitter Receptor Influence on Behavior
  • Life Sciences › Neuroscience › Cellular and Molecular Neuroscience › Neuroscience and Neuropharmacology Research
Keywords
cannabinoids, endocannabinoid system, reward processing, addiction, cannabis use disorder, delta-9-tetrahydrocannabinol, synthetic cannabinoids, CB1 receptor, dopamine, ventral tegmental area, drug craving, relapse, corticostriatal pathway, fatty acid amide hydrolase inhibitors, allosteric modulators, cannabidiol, alcoholism, opioid use disorder
MeSH terms
Animals, Cannabinoids, Marijuana Abuse, Humans, Reward, Behavior, Addictive, Receptors, Cannabinoid, Drug-Seeking Behavior, Endocannabinoids

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Cannabinoids and the endocannabinoid system in reward processing and addiction: from mechanisms to interventions. https://app.cochat.ai/papers/10.31887/dcns.2020.22.3/rspanagel
The paper
Spanagel, R. (2020). Cannabinoids and the endocannabinoid system in reward processing and addiction: from mechanisms to interventions. Dialogues in Clinical Neuroscience. https://doi.org/10.31887/dcns.2020.22.3/rspanagel

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.